Tianjin Medical University Cancer Institute And Hospital

This phase 2 trial tests whether combining an immunotherapy drug (iparomlimab/tuvonralimab), targeted radiation, and the drug lenvatinib can improve outcomes for people with intermediate-stage liver cancer that may be removable by surgery. Participants receive the combination bef…

This study looks at whether high-precision radiation therapy, delivered by the Edge system, can improve outcomes for people with spinal metastases from solid tumors. After surgery to relieve pressure on the spinal cord, patients receive radiation in five sessions to target remain…

This trial tests whether adding a procedure called irreversible electroporation (IRE) to standard targeted immunotherapy can help people with unresectable liver cancer that has spread into the portal vein. About 60 adults who have already received three cycles of immunotherapy wi…

This trial tests whether adding a procedure called irreversible electroporation (IRE) after chemotherapy helps people with locally advanced pancreatic cancer that cannot be surgically removed. About 60 adults who have stable or shrinking tumors after three cycles of chemotherapy …

This trial tests whether a technique called irreversible electroporation (IRE) can help people with a type of bile duct cancer that cannot be removed by surgery. IRE uses high-voltage electric pulses to create tiny holes in tumor cell membranes, causing the cells to die without t…

This trial is testing whether adding the immunotherapy drug enlonstobart to standard chemotherapy and radiation can improve outcomes for people with locally advanced cervical cancer. Participants first receive enlonstobart with chemotherapy, then continue enlonstobart alongside c…

This phase 2 study is testing fluzoparib, a daily pill, as a maintenance therapy for people with advanced triple-negative breast cancer whose disease was controlled by platinum chemotherapy. The trial will enroll 72 participants with or without BRCA gene mutations. The goal is to…

This phase 3 study tests whether giving two drugs (tislelizumab and lenvatinib) before surgery can help prevent liver cancer from returning in patients at high risk of recurrence. About 198 adults with early-stage liver cancer will be enrolled. The main goal is to see if this app…

This phase II trial is testing whether combining two drugs—glofitamab and chidamide—can help people with diffuse large B-cell lymphoma that has come back or not responded to earlier treatment. The study will enroll about 22 adults and measure how many achieve a complete response …

This trial is investigating the best time to give immunotherapy for people with advanced esophageal cancer that cannot be removed by surgery. Participants will receive either immunotherapy before chemoradiation or after, to see which sequence helps control the cancer longer. The …

This study tests a new combination of three drugs (chidamide, rituximab, and polatuzumab vedotin) in elderly patients with a specific type of untreated lymphoma called double-positive DLBCL. The goal is to see how many patients achieve complete remission after treatment. About 58…

This phase II trial is testing whether freezing tumors (cryoablation) before giving an experimental immunotherapy drug called rilafup α along with standard chemotherapy can help shrink or control advanced bile duct and gallbladder cancers. The study enrolls 30 people who have not…

This trial is investigating whether giving tislelizumab (an immunotherapy drug) combined with chemotherapy for 2 cycles before surgery works as well as 4 cycles in people with locally advanced head and neck squamous cell carcinoma. The study aims to find the best balance between …

This phase II trial tests two drugs—becotatug vedotin and pucotenlimab—given before surgery to people with advanced hypopharyngeal cancer. The goal is to shrink tumors enough to improve surgical outcomes and possibly preserve the voice box. About 52 participants will receive thre…

This study tests a procedure that uses microwave energy to destroy part of the spleen while temporarily blocking its main artery. The goal is to improve low blood cell counts in people with severe hypersplenism caused by cirrhosis. About 35 adults whose blood counts have not resp…

This trial tests whether giving the immunotherapy drug durvalumab along with chemotherapy before surgery can shrink biliary tract cancers and improve outcomes. About 40 people with resectable tumors will receive the combination, then undergo surgery. The goal is to see if this ap…

This clinical trial is testing a combination of three drugs—entinostat, pyrotinib, and endocrine therapy—in people with advanced triple-positive breast cancer (cancer that is both hormone receptor-positive and HER2-positive) whose disease has worsened after prior treatment with t…

This study tests a shorter, higher-dose-per-day radiation schedule (hypofractionated radiotherapy) given after complete surgical removal of stage II or III thymic epithelial tumors. The goal is to see if this approach is safe and tolerable, while also checking how well it control…

This Phase 3 trial tests whether adding the targeted drug surufatinib to standard chemotherapy before surgery helps more patients with high-risk pancreatic cancer have their tumors completely removed. About 106 adults with resectable or borderline resectable pancreatic cancer wil…

This study tests a new treatment for people with extensive-stage small cell lung cancer who have not had treatment before. The approach combines the drug bemotuzumab with standard chemotherapy and another drug called anlotinib, followed by chest radiation. The goal is to see if t…

This trial investigates whether adding a Braun anastomosis—a connection between two loops of the small intestine—during pancreatic cancer surgery can lower the risk of delayed gastric emptying, a frequent complication where the stomach takes too long to empty. About 264 adults sc…

This phase 3 trial tests whether adding radiotherapy to standard chemotherapy after pancreatic cancer surgery can prevent the cancer from coming back. It enrolls 288 high-risk patients who have had surgery but still have factors like positive margins or lymph node involvement. Pa…

This phase II trial tests a combination of four drugs—chidamide, dinutuximab beta, irinotecan, and temozolomide—in 27 children whose neuroblastoma has returned or not responded to standard treatment. The goal is to see how well the regimen controls the cancer and to monitor side …

This phase 2 trial is testing a combination of three drugs (liposomal irinotecan, capecitabine, and enlonstobart) plus a short course of radiation before surgery for people with locally advanced rectal cancer. The goal is to see if this approach can completely eliminate the tumor…

This study looks at two approaches for people with a type of esophageal cancer that shrank after initial chemo-immunotherapy. One group will have surgery to remove the tumor, while the other will get a combination of radiation and chemotherapy instead. Both groups will also recei…

This study tests two surgical techniques for bile duct cancer that has spread to nearby lymph nodes. One method removes the bile duct completely to take out all affected lymph nodes, while the other leaves the bile duct in place but may leave some lymph tissue behind. The goal is…

This study tests whether adding the immunotherapy drug iparomlimab after standard chemoradiation can help older adults (70+) with inoperable esophageal cancer live longer without the disease getting worse. About 52 participants will receive the drug for one year after chemoradiat…

This study tests whether adding an immunotherapy drug (sintilimab) to short-course radiation and chemotherapy can improve long-term survival in people with a common type of locally advanced rectal cancer (MSS type). About 130 adults aged 18-75 with stage II/III rectal cancer will…

This study tests whether a sequence of treatments—chemotherapy infused into the liver, two drugs (durvalumab and bevacizumab), and targeted radiation—can shrink advanced liver cancer enough to allow surgery. About 30 adults with liver cancer that cannot currently be removed will …

This phase II trial tests a combination of four treatments—two immunotherapies (ipilimumab N01 and sintilimab), a targeted therapy (bevacizumab biosimilar), and chemotherapy directly into the liver—for people with advanced liver cancer that cannot be surgically removed. The goal …

This phase 2 trial tests a new radiation technique called lattice radiation therapy (LRT) combined with immunotherapy in 30 people with advanced solid tumors that have not responded to standard treatments. LRT delivers high doses of radiation to small spots inside the tumor while…

This study tests a combination of two drugs (Sacituzumab Tirumotecan and Furmonertinib) in 25 people with advanced non-squamous non-small cell lung cancer that has an EGFR gene mutation and has stopped responding to standard treatments. The goal is to see if the combo can shrink …

This study tests a new approach for people with advanced non-small cell lung cancer whose disease has worsened after initial immunotherapy and chemotherapy. Participants will receive a combination of microwave ablation (using heat to destroy tumors), the immunotherapy drug tislel…

This study tests a combination of four drugs (sintilimab, ipilimumab, cetuximab, and dabrafenib) in people with a specific type of advanced colorectal cancer that has a BRAF V600E mutation and is microsatellite stable. These cancers are hard to treat and don't respond well to sta…

This phase II trial is testing a new way to treat lung cancer that has spread to the brain. It combines a targeted cancer pill (osimertinib) with a special type of whole-brain radiation that tries to protect the memory center (hippocampus). The study will enroll 74 people with a …

This phase 2 trial tests whether adding two newer drugs—serplulimab (an immunotherapy) and nimotuzumab (a targeted therapy)—to standard chemoradiation before surgery can improve outcomes for people with resectable esophageal cancer. About 46 participants will receive the combinat…

This study tests whether giving additional immune therapy after surgery can help prevent head and neck cancer from coming back. It includes 268 adults who already had a good response to initial treatment. The goal is to see if this approach improves survival and is safe.

This study tests a two-step approach for people with advanced esophageal cancer that cannot be removed by surgery. First, patients receive a combination of immunotherapy and chemotherapy. Then, based on how well the tumor responds, they get either the same drugs plus radiation or…

This phase 2 trial is testing a combination of five drugs (iparomlimab, tuvonralimab, chidamide, nab-paclitaxel, and gemcitabine) as a first treatment for people with metastatic pancreatic cancer. The study aims to see if this mix can shrink tumors and improve survival. It will e…

This early study tests a new cell therapy called GK01, made from a patient's own immune cells, for advanced solid tumors. Fifteen participants will receive GK01 alone or with chemotherapy after surgery. The main goal is to check safety, not yet to prove it works.

This phase II trial is testing whether adding the immunotherapy drug serplulimab to standard chemoradiotherapy can help people with locally advanced cervical cancer live longer without their disease getting worse. About 216 participants who have not yet been treated will receive …

This study tests a new treatment for people with a certain type of lung cancer (non-small cell lung cancer) who had surgery but still had cancer cells left. The treatment combines a cell therapy made from the patient's own immune cells (L-TIL) with an immunotherapy drug (tisleliz…

This phase II trial is testing whether a new immune cell treatment called WAST cells, combined with the chemotherapy drug docetaxel, can shrink tumors or slow disease in people with advanced non-small cell lung cancer that has stopped responding to PD-1 inhibitors. The study plan…

This study tests whether adding the drug serplulimab to standard chemoradiotherapy after surgery can help prevent cervical cancer from returning in patients with multiple risk factors. About 134 women aged 18-65 with PD-L1 positive cervical cancer will be randomly assigned to rec…

This study tests a combination of furmonertinib (a targeted pill), chemotherapy injected into the spine, and precise radiation for people with a specific type of lung cancer (EGFR mutation) that has spread to the brain and its lining. The goal is to see if this approach can contr…

This phase 2 trial is testing whether women with certain aggressive breast cancers (triple negative or HER2-positive) can safely avoid breast surgery if their tumors disappear completely after a combination of chemotherapy and radiation. The study will enroll 200 women and follow…

This study tests whether anlotinib hydrochloride capsules can help prevent lung cancer from coming back in patients who still had cancer cells after surgery and chemotherapy. About 64 adults with stage IIA-IIIA non-small cell lung cancer will take the drug daily. The main goal is…

This trial is testing whether a combination of two drugs, fosrolapitant and palonosetron, can prevent nausea and vomiting in cancer patients receiving trastuzumab rezetecan therapy. About 56 adults scheduled for this targeted treatment will receive the antiemetic combination intr…

This study tests whether a specially trained nurse-led team can help people recover better after head and neck cancer surgery. The team includes nurses, doctors, dietitians, and counselors who create a personalized care plan. Researchers will compare 80 patients who get this extr…

This study tests whether a medicated nasal spray (dexmedetomidine) can help women feel relaxed and less anxious during breast-conserving surgery for breast cancer. About 394 women will receive either the spray or a placebo before surgery. Researchers will measure sedation levels,…

This study investigates whether the unique bacteria found inside digestive system tumors can help predict how well a patient will respond to neoadjuvant therapy (chemotherapy before surgery). Researchers will analyze tumor samples from 90 adults with pancreatic, gastric, colorect…

This study tests a new AI chatbot that gives personalized health information to people with thyroid cancer before and after surgery. Researchers want to see if using the chatbot helps patients feel more ready to go home and recover better compared to standard education. About 150…

This study tests a new abdominal pressure device that helps limit breathing movement during radiation therapy for lung cancer. Researchers want to see if it safely reduces tumor motion, making treatment more accurate. About 50 adults with early-stage lung cancer will take part. T…

This real-world study follows 245 people with HR+/HER2- advanced breast cancer who are taking CDK4/6 inhibitors combined with hormone therapy. Researchers want to see how long the treatment controls the cancer and what options work best after the cancer becomes resistant. The goa…

This study aims to find the best range for removing No.4sb lymph nodes during surgery for advanced stomach cancer. Researchers will track 400 patients to see how often cancer spreads to different parts of these lymph nodes. The goal is to help surgeons remove only the necessary n…

This prospective, multicenter, single-arm phase II clinical trial is designed to enroll patients with spinal metastases classified as Bilsky grade 1c-3 who will receive stereotactic body radiation therapy (SBRT). The objective of this study is to assess the efficacy and safety of…